PD-IF-032 is a siRNA loaded into exosome to suppress PD-L1 expression with high target-specificity. Overexpression of PD-L1 on tumor cells is responsible for T cell hyporesponsiveness. Through knockdown of PD-L1, PD-IF-032 blocks PD-1/PD-L1 bindings to re-sensitize cancer to T cell killing. For the transportation of siRNA targeting PD-L1 into cancer cells, we constructed exosome with intrinsic long-term circulatory capability and excellent biocompatibility.


In the tumor microenvironment, PD-L1 (also known as B7-H1 or CD274) is expressed on a wide range of non-hematopoietic cells including those and PD-1 is generally expressed on T cells and hematopoietic cells. PD-L1 is also expressed on cancer cells such as melanoma, non-small cell lung cancer, renal cell carcinoma, gastric cancer, leukemia, and multiple myeloma.

PD-1/PD-L1 interaction triggers functional exhaustion of tumor-reactive cytotoxic T cells, thus allowing tumors to evade antitumor immunity. Blocking PD-1/PD-L1 interactions in tumors can reverse T cell exhaustion and induce significant anti-tumor responses and has thus emerged as a promising strategy for cancer immunotherapy.


PD-IF-032 could be used alone or in combination to treat tumor patients who overexpress PD-L1.

Pushing the boundaries for life science research

Pharma company is on a mission to advance our proprietary platform for gene therapy and to transform the lives of patients through effective therapies.

Copyright © Acevirt. All rights reserved.